Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics

Author(s): Chiara Nardon, Dolores Fregona

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 3 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


In the last decade, we have been developing some gold(III) derivatives showing interesting antitumor properties and reduced systemic and renal toxicity, compared to the clinically-established reference drug cisplatin. Starting from the rationale at the base of our investigations, this review has been divided into two sections, with respect to our patented first- (aminoderivatives) and secondgeneration (peptidomimetics) potential drugs. Every section describes the in vitro and in vivo anticancer activity of the compounds, chosen as models, towards different types of tumor. In particular, we summarize the results achieved so far, in particular taking into account the latest in-depth studies related to their activity, mechanism of action and toxicological profile. Taken together, our data could open up new prospects for further advanced preclinical pharmacological testing.

Keywords: Antitumor drugs, Apoptosis, Dithiocarbamate, Gold complexes, Peptides, Proteasome, Thioredoxin, Toxicity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 08 October, 2015
Page: [360 - 380]
Pages: 21
DOI: 10.2174/1568026615666150827094500
Price: $65

Article Metrics

PDF: 35